This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Syndax Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Plug Power (PLUG) to Report Q4 Earnings: What to Expect?
by Zacks Equity Research
Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.
Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Syndax (SNDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 10.53% and -0.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 18.68% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares
by Zacks Equity Research
Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares
4 of the Best Stocks to Buy on Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that majority of successful stocks see acceleration in earnings before a positive stock price movement
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
Why These 4 Biotech Stocks May Not Lose Momentum Soon
by Zacks Equity Research
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.